Galderma Laboratories, L.P. v. Perrigo UK FINCO L.P.
1:16-cv-00732
Overview
Parties
Defendant
Perrigo UK FINCO L.P. Operating Company
Represented By
7 Attorneys ListedPhillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Plaintiff
Galderma Laboratories, L.P. NPE (Individual / Inventor)
Represented By
4 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Counter Claimant
Perrigo Co. Operating Company
Represented By
2 Attorneys ListedPhillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Counter Defendant
Nestle Skin Health S.A. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 25 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇨🇳 China | China Counterpart | View Official Patent → | |
| 🇨🇳 China | China Counterpart | View Official Patent → | |
| 🇨🇦 Canada | Canada Counterpart | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → | |
| 🇪🇺 European Patent Office (UPC States) | European Counterpart (EP) | View Official Patent → | |
| 🇪🇺 European Patent Office (UPC States) | European Counterpart (EP) | View Official Patent → | |
| 🇨🇳 China | China Counterpart | View Official Patent → | |
| 🇨🇳 China | China Counterpart | View Official Patent → | |
| 🇪🇺 European Patent Office (UPC States) | European Counterpart (EP) | View Official Patent → | |
| 🇪🇺 European Patent Office (UPC States) | European Counterpart (EP) | View Official Patent → | |
| 🇨🇳 China | China Counterpart | View Official Patent → | |
| 🇨🇳 China | China Counterpart | View Official Patent → | |
| 🇨🇳 China | China Counterpart | View Official Patent → | |
| 🇨🇳 China | China Counterpart | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 6 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7439241
Compounds, formulations, and methods for treating or preventing rosacea
|
Filed: 2004-05-25
Issued: 2008-10-21
|
Expired (Term Ended)
+457d PTA
Expires: 2025-08-25
|
|
|
US8410102
Methods and compositions for treating or preventing erythema
|
Filed: 2011-03-25
Issued: 2013-04-02
|
Expired (Term Ended)
Expires: 2024-10-23
|
|
|
US8426410
Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
|
Filed: 2009-08-21
Issued: 2013-04-23
|
Expired (Term Ended)
Expires: 2024-09-10
|
|
|
US8859551
Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
|
Filed: 2013-02-25
Issued: 2014-10-14
|
Expired (Term Ended)
Expires: 2025-01-10
|
|
|
US8513247
Methods and compositions for safe and effective treatment of erythema
|
Filed: 2011-03-25
Issued: 2013-08-20
|
Active (4.3 yrs remaining)
Expires: 2031-03-25
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.
High PTA (+457 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).